Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laurent, Gilardin"'
Autor:
Lubka T. Roumenina, David C. Fritzinger, Carl-Wilhelm Vogel, Véronique Frémeaux-Bacchi, Ivan Peyron, Srinivas V. Kaveri, Sandrine Delignat, Julie Rayes, Mathieu Ing, Sébastien Lacroix-Desmazes, Laurent Gilardin
Publikováno v:
Haematologica
Haematologica, Ferrata Storti Foundation, 2018, 103 (2), pp.351-360. ⟨10.3324/haematol.2017.165720⟩
Haematologica, Ferrata Storti Foundation, 2018, 103 (2), pp.351-360. ⟨10.3324/haematol.2017.165720⟩
International audience; Development of neutralizing antibodies against therapeutic Factor VIII (FVIII) is the most serious complication of the treatment of hemophilia A. There is growing evidence to show the multifactorial origin of the anti-FVIII im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30b199580c64b903f1f4d835862415d6
https://hal.sorbonne-universite.fr/hal-01831993/document
https://hal.sorbonne-universite.fr/hal-01831993/document
Autor:
Jordan D. Dimitrov, Sandrine Delignat, Y.C. Lone, Sébastien Lacroix-Desmazes, Yohann Repessé, Srini V. Kaveri, Laurent Gilardin
Publikováno v:
Haemophilia. 20:486-492
The administration of therapeutic factor VIII (FVIII) to treat or prevent haemorrhages in haemophilia A patients results, in up to 30% of the cases, in the development of inhibitory anti-FVIII antibodies. Much debate has taken place on the relevance
Autor:
Laurent Gilardin, Anastas Pashov, Srini V. Kaveri, T. Calvez, B. Maillère, A. Pavlova, Yohann Repessé, Johannes Oldenburg, Sébastien Lacroix-Desmazes
Publikováno v:
Haemophilia. 20:176-184
Summary Forty per cent of haemophilia A (HA) patients have missense mutations in the F8 gene. Yet, all patients with identical mutations are not at the same risk of developing factor VIII (FVIII) inhibitors. In severe HA patients, human leucocyte ant
Autor:
Séverine Padiolleau-Lefèvre, Meenu Sharma, Ankit Mahendra, Didier Boquet, Ivan Peyron, Sébastien Lacroix-Desmazes, Laurent Gilardin, Bharath Wootla, Olivier Thaunat, Abhijit More, Srini V. Kaveri, Navin Varadarajan, Cécile Dollinger, Christophe Legendre, Desirazu N. Rao
Publikováno v:
Journal of Immunology
Journal of Immunology, 2016, 196 (10), pp.4075-4081. ⟨10.4049/jimmunol.1403005⟩
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2016, 196, pp.4075-4081
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2016, 196 (10), pp.4075-4081. ⟨10.4049/jimmunol.1403005⟩
Journal of Immunology, 2016, 196 (10), pp.4075-4081. ⟨10.4049/jimmunol.1403005⟩
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2016, 196, pp.4075-4081
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2016, 196 (10), pp.4075-4081. ⟨10.4049/jimmunol.1403005⟩
The origin and physiopathological relevance of catalytic antibodies is not well understood owing to the fact that catalytic antibodies have been studied in relatively small cohorts of patients with rare diseases and/or without systematic follow-up. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb71d2ae1b8e727c38f5f340038b071
https://hal.science/hal-01922046
https://hal.science/hal-01922046